Administration of 4-(<i>α</i>-L-Rhamnosyloxy)-benzyl Isothiocyanate Delays Disease Phenotype in SOD1<sup>G93A</sup> Rats: A Transgenic Model of Amyotrophic Lateral Sclerosis

<div>GMG-ITC chromatogram. HPLC chromatogram of 4-(<i>α</i>-L-rhamnosyloxy)-benzyl isothiocyanate (GMG-ITC) produced by myrosinase catalyzed hydrolysis of purified 4-(<i>α</i>-L-rhamnosyloxy)-benzyl glucosinolate (glucomoringin, GMG).</div>

BioMed Research International

fig3

Figure 3

Figure 3: Administration of 4-(<i>α</i>-L-Rhamnosyloxy)-benzyl Isothiocyanate Delays Disease Phenotype in SOD1<sup>G93A</sup> Rats: A Transgenic Model of Amyotrophic Lateral Sclerosis 

Figure 3 | Administration of 4-(α-L-Rhamnosyloxy)-benzyl Isothiocyanate Delays Disease Phenotype in SOD1G93A Rats: A Transgenic Model of Amyotrophic Lateral Sclerosis 